Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Staging of High-risk and Non-metastatic Renal Cell Carcinoma Preoperatively Model Predicts Pathologic T3 Stage for Neoadjuvant Clinical Trial Enrollment.

Urology·2026
Same author

Quantitative Diffusion and T2 Mapping Using RF-Modulated Phase-Based Gradient Echo Imaging.

Magnetic resonance in medicine·2026
Same author

Genetic loss of CHD1 regulates distinct histone post-translational modifications in the development of castration-resistant prostate cancer.

Neoplasia (New York, N.Y.)·2026
Same author

Percutaneous Microwave Ablation Preserves Renal Function with Similar Long Term Oncologic Outcomes Compared to Surgery for Clinical T1 Renal Cell Carcinoma.

Cancers·2026
Same author

Histone-modifying enzymes as drivers and therapeutic targets in androgen-resistant prostate cancer.

Frontiers in endocrinology·2026
Same author

MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer.

Cancer research·2026

Related Experiment Video

Updated: Jun 21, 2026

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
07:39

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Published on: June 28, 2019

A high-throughput method to identify novel senescence-inducing compounds.

Jonathan A Ewald1, Noel Peters, Joshua A Desotelle

  • 1Department of Urology, University of Wisconsin-Madison, Madison, Wisconsin 53792, USA.

Journal of Biomolecular Screening
|July 31, 2009
PubMed
Summary
This summary is machine-generated.

Researchers developed a new method to find compounds that trigger cellular senescence, a key process for cancer therapy. This high-throughput screening identified four novel compounds for further study in cancer treatment.

More Related Videos

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells
08:56

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells

Published on: July 12, 2022

A Simple Method for High Throughput Chemical Screening in Caenorhabditis Elegans
08:49

A Simple Method for High Throughput Chemical Screening in Caenorhabditis Elegans

Published on: March 20, 2018

Related Experiment Videos

Last Updated: Jun 21, 2026

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
07:39

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Published on: June 28, 2019

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells
08:56

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells

Published on: July 12, 2022

A Simple Method for High Throughput Chemical Screening in Caenorhabditis Elegans
08:49

A Simple Method for High Throughput Chemical Screening in Caenorhabditis Elegans

Published on: March 20, 2018

Area of Science:

  • Oncology
  • Cell Biology
  • Drug Discovery

Background:

  • Cellular senescence is a stable cell cycle arrest that holds promise for cancer therapy.
  • Inducing cellular senescence as a cancer treatment strategy is gaining interest but lacks efficient methods.
  • Identifying novel compounds that reliably induce senescence has been a significant challenge.

Purpose of the Study:

  • To develop and validate a high-throughput screening method for identifying compounds that induce cellular senescence in cancer cells.
  • To screen a diverse library of known bioactive compounds and natural products for senescence-inducing agents.
  • To identify novel lead compounds that can be further investigated for their therapeutic potential in cancer treatment.

Main Methods:

  • A semiautomated, 96-well plate-based assay was designed to screen compound libraries.
  • Primary hits were identified by measuring low cell numbers using Hoechst 33342 fluorescence after 3 days.
  • Secondary validation involved senescence-associated beta-galactosidase staining and morphological assessment to distinguish senescence from other cellular fates.

Main Results:

  • A library of 4160 compounds was screened at a 10-microM dose.
  • The assay successfully identified compounds inducing persistent growth arrest and increased expression of senescence markers.
  • Four novel lead compounds, not previously linked to senescence, were identified for further research.

Conclusions:

  • A robust high-throughput screening method for identifying senescence-inducing compounds in cancer cells has been established.
  • This assay represents a significant advancement in the discovery of novel cancer therapeutics targeting cellular senescence.
  • The identified lead compounds offer promising avenues for developing new anti-cancer strategies based on senescence induction.